Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Bupropion/zonisamide
Другие языки:

Bupropion/zonisamide

Подписчиков: 0, рейтинг: 0
Bupropion/zonisamide
Bupropion and zonisamide.svg
Combination of
Bupropion Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
Zonisamide Sulfonamide anticonvulsant
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
  (verify)

Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity. Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor. The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.

See also



Новое сообщение